Gilead Sciences (NQ:GILD)

143.11 -1.63 (-1.13%)

Delayed Quote Updated: 10:36 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

78 79 Next >

2 Large-Cap Stocks to Consider Right Now and 1 That Underwhelm

July 21, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

Topics Supply Chain

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India

July 17, 2025

Via AB Newswire

Topics Death

Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment

July 15, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.

Via StockStory

Topics Artificial Intelligence

Which S&P500 stocks are gapping on Tuesday? ↗

July 15, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.

Via Chartmill

GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025

From The Schall Law Firm

Via Business Wire

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

July 14, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gilead Sciences, Inc. - GILD

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

July 14, 2025

From Gilead Sciences, Inc.

Via Business Wire

GILEAD SCIENCES INC (NASDAQ:GILD) – An Undervalued Biopharmaceutical Stock Worth Considering ↗

July 12, 2025

GILEAD SCIENCES INC (NASDAQ:GILD) appears undervalued with strong profitability and reasonable financial health, making it a potential candidate for value investors.

Via Chartmill

Bill Gates Warns Of 'Devestating Effects' Of USAID Funding Cuts: 'It's Not Too Late To Reverse Them' ↗

July 12, 2025

Bill Gates raises concerns over U.S. aid cuts' impact on HIV programs in Africa and calls for a reversal of the decision.

Via Benzinga

Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know

July 11, 2025

A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.

Via StockStory

Topics ETFs Stocks World Trade

Top S&P500 movers in Friday's session ↗

July 11, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

What's going on in today's session: S&P500 movers ↗

July 11, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments ↗

July 09, 2025

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year.

Via Stocktwits

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million ↗

July 09, 2025

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding uncertainty.

Via Benzinga

Gilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income Countries ↗

July 09, 2025

Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three years in countries supported by the Global Fund, at no profit to the company.

Via Stocktwits

How Do Investors Really Feel About Gilead Sciences? ↗

July 09, 2025

Via Benzinga

Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' ↗

July 09, 2025

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.

Via Benzinga

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

July 09, 2025

From Gilead Sciences, Inc.

Via Business Wire

GILEAD SCIENCES INC (NASDAQ:GILD) - A Strong Technical Setup for Breakout Investors ↗

July 07, 2025

GILEAD SCIENCES INC (NASDAQ:GILD) shows strong technicals and a high-quality breakout setup, making it a stock to watch for momentum traders.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 06, 2025

From Pomerantz LLP

Via GlobeNewswire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

July 05, 2025

Via Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

July 03, 2025

Via Benzinga

Better Dividend ETF to Buy for Passive Income: SCHD or GCOW ↗

July 03, 2025

Via The Motley Fool

Topics ETFs Stocks

2 Profitable Stocks to Keep an Eye On and 1 to Avoid

July 03, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Gilead Sciences: A Mixed Bag of Opportunities and Risks ↗

July 01, 2025

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

July 01, 2025

From Pomerantz LLP

Via GlobeNewswire

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.